📊 JBIO Key Takeaways
Is JBIO a Good Investment? Thesis Analysis
Pre-revenue biotech company facing critical cash runway crisis with less than 12 months of operations funded at current burn rate. Accelerating net losses (-27.2% YoY) and $94.7M annual operating cash burn against only $88.4M cash position create severe financial distress requiring immediate capital infusion or revenue generation to avoid potential restructuring.
Why Buy JBIO? Key Strengths
- Zero debt capital structure eliminates refinancing risk and limits downside
- Excellent liquidity position (21.09x current ratio) enables continued near-term operations
- Substantial stockholders' equity base ($332.5M) provides bankruptcy cushion and dilution capacity
JBIO Investment Risks to Consider
- Critical cash runway of approximately 11 months at current burn rate with no path to profitability visible
- Accelerating net losses ($127.4M) with 27.2% year-over-year deterioration indicates worsening financial condition
- Massive operating cash burn ($94.7M annually) against zero revenue indicates pre-commercialization biotech with execution risk
- Severe shareholder dilution inevitable as company will require emergency capital raise to survive
- Negative ROE (-38.3%) and ROA (-36.4%) indicate value destruction at current burn trajectory
Key Metrics to Watch
- Quarterly operating cash flow trend and remaining months of runway
- Revenue generation or commercialization milestone announcements
- Capital raise announcements and dilution impact to existing shareholders
JBIO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 21.09x current ratio provides a solid financial cushion.
JBIO Profitability Ratios
JBIO vs Healthcare Sector
How Jade Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is JBIO Overvalued or Undervalued?
Based on fundamental analysis, Jade Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
JBIO Balance Sheet & Liquidity
JBIO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Jade Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.89 indicates the company is currently unprofitable.
JBIO Growth Metrics (YoY)
JBIO Capital Allocation
JBIO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Jade Biosciences, Inc. (CIK: 0001798749)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JBIO
What is the AI rating for JBIO?
Jade Biosciences, Inc. (JBIO) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are JBIO's key strengths?
Claude: Zero debt capital structure eliminates refinancing risk and limits downside. Excellent liquidity position (21.09x current ratio) enables continued near-term operations.
What are the risks of investing in JBIO?
Claude: Critical cash runway of approximately 11 months at current burn rate with no path to profitability visible. Accelerating net losses ($127.4M) with 27.2% year-over-year deterioration indicates worsening financial condition.
What is JBIO's revenue and growth?
Jade Biosciences, Inc. reported revenue of N/A.
Does JBIO pay dividends?
Jade Biosciences, Inc. does not currently pay dividends.
Where can I find JBIO SEC filings?
Official SEC filings for Jade Biosciences, Inc. (CIK: 0001798749) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JBIO's EPS?
Jade Biosciences, Inc. has a diluted EPS of $-3.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Jade Biosciences, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JBIO stock overvalued or undervalued?
Valuation metrics for JBIO: ROE of -38.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JBIO stock in 2026?
Our dual AI analysis gives Jade Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JBIO's free cash flow?
Jade Biosciences, Inc.'s operating cash flow is $-94.7M, with capital expenditures of $196.0K.
How does JBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -38.3% (avg: 15%), current ratio 21.09 (avg: 2).